Levosimendan

Generic Name: Levosimendan

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₂N_₆O

CAS Number: 141505-33-1

Unique Ingredient Identifier: C6T4514L4E

Background: Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication: For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions: Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure

Associated Therapies: Positive cardiac inotropic effect, Intravenous inotropic therapy

Clinical Trials

Levosimendan in High Risk Patients Undergoing Cardiac Surgery

Phase 4

Completed

Conditions: Low Cardiac Output Syndrome

Interventions: Drug: placebo
Drug: Levosimendan

First Posted Date: 2009-10-14

Last Posted Date: 2016-07-22

Lead Sponsor: Università Vita-Salute San Raffaele

Target Recruit Count: 1000

Registration Number: NCT00994825

Locations: 🇷🇺
Astrakhan Federal Centre for Cardiac Surgery, Astrakhan, Russia, Russian Federation
🇷🇺
Scientific Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia, Russian Federation
🇷🇺
Moscow Regional Clinical & Research Institute, Moscow, Russia, Russian Federation

and more 15 locations

Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure

Phase 4

Conditions: Advanced Heart Failure

Interventions: Drug: Levosimendan
Drug: Placebo

First Posted Date: 2009-10-02

Last Posted Date: 2013-09-18

Lead Sponsor: Hospital Universitario de Canarias

Target Recruit Count: 213

Registration Number: NCT00988806

Locations: 🇪🇸
Department of Cardiology. Hospital Universitario de Canarias, La Laguna, S.C. de Tenerife, Spain

Effects of Levosimendan on Microcirculation in Septic Shock

Phase 2

Completed

Conditions: Septic Shock

Interventions: Drug: Levosimendan
Drug: dobutamine

First Posted Date: 2008-12-02

Last Posted Date: 2009-10-15

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 40

Registration Number: NCT00800306

Locations: 🇮🇹
Departement of Anesthesiology and Intensive Care of the University of Rome "La Sapienza" Viale del Policlinico 155, Rome, Italy

Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables

Phase 2

Completed

Conditions: Transient Ischemic Attack
Stroke

Interventions: Drug: Placebo
Drug: Levosimendan

First Posted Date: 2008-06-17

Last Posted Date: 2009-11-25

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 32

Registration Number: NCT00698763

Locations: 🇫🇮
Helsinki University Hospital (HUCH), Helsinki, Finland
🇫🇮
Turku University Hospital (TYKS), Turku, Finland
🇩🇪
Heidelberg University Clinic, Heidelberg, Germany

and more 4 locations

Levosimendan in Congenital Cardiac Surgery

Not Applicable

Completed

Conditions: Congenital Cardiovascular Defects
Low Cardiac Output Syndrome

First Posted Date: 2008-06-12

Last Posted Date: 2010-01-26

Lead Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Target Recruit Count: 50

Registration Number: NCT00695929

Locations: 🇧🇪
Cliniques Universitaires Saint Luc, Brussels, Belgium

Levosimendan and Myocardial Protection

Phase 4

Completed

Conditions: Myocardial Protection

Interventions: Drug: levosimendan
Drug: Placebo

First Posted Date: 2008-02-07

Last Posted Date: 2008-02-07

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 100

Registration Number: NCT00610350

Locations: 🇮🇹
University of Rome "Sapienza", Rome, Italy

Myocardial Hemodynamic Effects of Levosimendan

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: levosimendan

First Posted Date: 2008-01-03

Last Posted Date: 2013-05-21

Lead Sponsor: University of Utah

Target Recruit Count: 10

Registration Number: NCT00585104

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Prophylactic Use of Levosimendan Versus Milrinone in Open Heart Surgery in Infants

Phase 2

Conditions: Low Cardiac Output Syndrome

Interventions: Drug: Levosimendan
Drug: Milrinone

First Posted Date: 2007-10-25

Last Posted Date: 2007-10-25

Lead Sponsor: Ludwig Boltzmann Gesellschaft

Target Recruit Count: 40

Registration Number: NCT00549107

Locations: 🇦🇹
Children´s Heart Center Linz, Linz, Austria

Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.

Phase 3

Completed

Conditions: Acute Heart Failure

First Posted Date: 2006-07-04

Last Posted Date: 2007-11-20

Lead Sponsor: Abbott

Target Recruit Count: 1300

Registration Number: NCT00348504

Locations: 🇺🇸
Global Medical Information - Abbott, Abbott Park, Illinois, United States

Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.

Phase 4

Completed

Conditions: Myocardial Infarction
Heart Failure
Cardiogenic Shock

Interventions: Drug: levosimendan
Drug: placebo,

First Posted Date: 2006-05-11

Last Posted Date: 2012-06-26

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 61

Registration Number: NCT00324766

Locations: 🇳🇴
Department of Cardiology, Ulleval University Hospital, Oslo, Norway

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy